<DOC>
	<DOC>NCT01420601</DOC>
	<brief_summary>To confirm the safety of the long-term use of TORISEL 25 mg for Intravenous Drip Infusion particularly for the onset of interstitial lung disease from Weeks 25 to 96 after the start of administration.</brief_summary>
	<brief_title>Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>Implemented as a Drug Use Investigation by Central Registration System</detailed_description>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma). Among patients registered and treated in the Special Investigation, Allcase Survey of Torisel, those continuously treated with Torisel for more than 24 weeks will be included. Patients not administered Torisel. Patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Torisel</keyword>
	<keyword>Long-term use</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>